RT Journal Article SR Electronic T1 Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer JF Clinical Cancer Research JO Clin Cancer Res FD American Association for Cancer Research SP 2895 OP 2899 DO 10.1158/1078-0432.CCR-07-2248 VO 14 IS 10 A1 Engelman, Jeffrey A. A1 Jänne, Pasi A. YR 2008 UL http://clincancerres.aacrjournals.org/content/14/10/2895.abstract AB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective therapies for non–small cell lung cancer patients whose tumors harbor somatic mutations in EGFR. All patients, however, ultimately develop resistance to these agents. Thus, there is a great need to understand how patients become resistant to develop effective therapies for these cancers. Studies over the last few years have identified two different EGFR tyrosine kinase inhibitor resistance mechanisms, a secondary mutation in EGFR, EGFR 790M, and amplification of the MET oncogene. These findings have led to clinical trials using newly designed targeted therapies that can overcome these resistance mechanisms and have shown promise in laboratory studies. Ongoing research efforts will likely continue to identify additional resistance mechanisms, and these findings will hopefully translate into effective therapies for non–small cell lung cancer patients.